

Maureen P M H Rutten-Van Mäjlken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1775959/publications.pdf>

Version: 2024-02-01

236
papers

12,563
citations

46918

47
h-index

29081

104
g-index

245
all docs

245
docs citations

245
times ranked

11806
citing authors

#	ARTICLE	IF	CITATIONS
1	The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis. <i>Value in Health</i> , 2022, 25, 1428-1438.	0.1	13
2	Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 501-524.	1.0	19
3	Value-based person-centred integrated care for frail elderly living at home: a quasi-experimental evaluation using multicriteria decision analysis. <i>BMJ Open</i> , 2022, 12, e054672.	0.8	5
4	Heterogeneity in preferences for outcomes of integrated care for persons with multiple chronic diseases: a latent class analysis of a discrete choice experiment. <i>Quality of Life Research</i> , 2022, 31, 2775-2789.	1.5	1
5	Moving Beyond Quality-Adjusted Life-Years in Elderly Care: How Can Multicriteria Decision Analysis Complement Cost-Effectiveness Analysis in Local-Level Decision Making. <i>Value in Health</i> , 2022, 25, 1717-1725.	0.1	3
6	Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis. <i>JMIR Cardio</i> , 2022, 6, e31302.	0.7	1
7	Economic Evaluation of Integrated Care. , 2021, , 575-593.		0
8	The impact of the involvement of a healthcare professional on the usage of an eHealth platform: a retrospective observational COPD study. <i>Respiratory Research</i> , 2021, 22, 88.	1.4	12
9	Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. <i>Pharmacoeconomics</i> , 2021, 39, 771-788.	1.7	24
10	Drivers of successful implementation of integrated care for multi-morbidity: Mechanisms identified in 17 case studies from 8 European countries. <i>Social Science and Medicine</i> , 2021, 277, 113728.	1.8	27
11	Bundled payments for chronic diseases increased health care expenditure in the Netherlands, especially for multimorbid patients.. <i>Health Policy</i> , 2021, 125, 751-759.	1.4	10
12	Early palliative care associated with lower costs for adults with advanced cancer: evidence from Hungary. <i>European Journal of Cancer Care</i> , 2021, 30, e13473.	0.7	2
13	Evaluating Complex Health and Social Care Program Using Multi-Criteria Decision Analysis: A Case Study of "Better Together in Amsterdam North". <i>Value in Health</i> , 2021, 24, 966-975.	0.1	4
14	Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study. <i>Value in Health</i> , 2021, 24, 1667-1675.	0.1	3
15	Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β_2 -agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. <i>BMJ Open</i> , 2021, 11, e049675.	0.8	3
16	Evaluating an integrated care pathway for frail elderly patients in Norway using multi-criteria decision analysis. <i>BMC Health Services Research</i> , 2021, 21, 884.	0.9	4
17	Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure. <i>Value in Health</i> , 2021, 24, 1435-1445.	0.1	3
18	Evaluating Complex Interventions. , 2021, , 611-627.		0

#	ARTICLE	IF	CITATIONS
19	Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: The randomized controlled NUTRAIN trial. <i>Clinical Nutrition</i> , 2020, 39, 405-413.	2.3	27
20	Comparing patients' and other stakeholders' preferences for outcomes of integrated care for multimorbidity: a discrete choice experiment in eight European countries. <i>BMJ Open</i> , 2020, 10, e037547.	0.8	13
21	The patient at the centre: evidence from 17 European integrated care programmes for persons with complex needs. <i>BMC Health Services Research</i> , 2020, 20, 1102.	0.9	19
22	How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , 2020, 40, 619-632.	1.2	12
23	Exploring characteristics of COPD patients with clinical improvement after integrated disease management or usual care: post-hoc analysis of the RECODE study. <i>BMC Pulmonary Medicine</i> , 2020, 20, 176.	0.8	1
24	The risk of overestimating cost savings from hospital-at-home schemes: A literature review. <i>International Journal of Nursing Studies</i> , 2020, 109, 103652.	2.5	12
25	Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients. <i>European Journal of Health Economics</i> , 2020, 21, 557-572.	1.4	13
26	Implementation of palliative care consult Service in Hungary – integration barriers and facilitators. <i>BMC Palliative Care</i> , 2020, 19, 41.	0.8	11
27	COVID-19 Contact Tracing Apps: Predicted Uptake in the Netherlands Based on a Discrete Choice Experiment. <i>JMIR MHealth and UHealth</i> , 2020, 8, e20741.	1.8	99
28	Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. <i>Croatian Medical Journal</i> , 2020, 61, 252-259.	0.2	5
29	The disease burden of multimorbidity and its interaction with educational level. <i>PLoS ONE</i> , 2020, 15, e0243275.	1.1	12
30	TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. <i>Pharmacoeconomics</i> , 2019, 37, 1391-1408.	1.7	33
31	What Is the Potential of Tissue-Engineered Pulmonary Valves in Children?. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1845-1853.	0.7	22
32	The Fold-in, Fold-out Design for DCE Choice Tasks: Application to Burden of Disease. <i>Medical Decision Making</i> , 2019, 39, 450-460.	1.2	4
33	Exploring the Impact of Adding a Respiratory Dimension to the EQ-5D-5L. <i>Medical Decision Making</i> , 2019, 39, 393-404.	1.2	14
34	Evaluation of integrated care services in Catalonia: population-based and service-based real-life deployment protocols. <i>BMC Health Services Research</i> , 2019, 19, 370.	0.9	31
35	Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results. <i>International Journal of COPD</i> , 2019, Volume 14, 447-456.	0.9	5
36	Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. <i>BMC Health Services Research</i> , 2019, 19, 131.	0.9	10

#	ARTICLE	IF	CITATIONS
37	Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine. <i>Value in Health</i> , 2019, 22, 313-321.	0.1	14
38	Bioprosthetic aortic valve replacement in elderly patients: Meta-analysis and microsimulation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 2189-2197.e14.	0.4	17
39	Beyond the clinical impact of aortic and pulmonary valve implantation: health-related quality of life, informal care and productivity. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 751-759.	0.6	1
40	Digital Health Transformation of Integrated Care in Europe: Overarching Analysis of 17 Integrated Care Programs. <i>Journal of Medical Internet Research</i> , 2019, 21, e14956.	2.1	52
41	Integrated Care for Frail Elderly: A Qualitative Study of a Promising Approach in The Netherlands. <i>International Journal of Integrated Care</i> , 2019, 19, 16.	0.1	17
42	How much does a heart valve implantation cost and what are the health care costs afterwards?. <i>Open Heart</i> , 2018, 5, e000672.	0.9	19
43	Systematic review of model-based economic evaluations of heart valve implantations. <i>European Journal of Health Economics</i> , 2018, 19, 241-255.	1.4	12
44	The SELFIE framework for integrated care for multi-morbidity: Development and description. <i>Health Policy</i> , 2018, 122, 12-22.	1.4	149
45	Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis. <i>Value in Health</i> , 2018, 21, 193-202.	0.1	11
46	Relevant models and elements of integrated care for multi-morbidity: Results of a scoping review. <i>Health Policy</i> , 2018, 122, 23-35.	1.4	103
47	Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries. <i>BMJ Open</i> , 2018, 8, e021072.	0.8	21
48	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0205013.	1.1	9
49	Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA). <i>BMC Health Services Research</i> , 2018, 18, 576.	0.9	43
50	Towards incentivising integration: A typology of payments for integrated care. <i>Health Policy</i> , 2018, 122, 963-969.	1.4	51
51	Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results. , 2018, , .		0
52	Clinical outcome and cost-effectiveness of 1-year nutritional intervention program in COPD. , 2018, , .		0
53	Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. <i>Medical Decision Making</i> , 2017, 37, 453-468.	1.2	24
54	Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. <i>Medical Decision Making</i> , 2017, 37, 469-480.	1.2	29

#	ARTICLE	IF	CITATIONS
55	Comparison of cardiovascular risk algorithms in patients with <i>vs</i> without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 777-786.	0.9	28
56	External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. <i>Value in Health</i> , 2017, 20, 397-403.	0.1	23
57	Comprehensive Diagnostic Assessment of Health Status of Patients with Asthma or COPD: A Delphi Panel Study among Dutch Experts. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 190-199.	0.7	5
58	PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 609-619.	0.2	5
59	Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. <i>Value in Health</i> , 2017, 20, 1260-1269.	0.1	32
60	Assessment of Burden of COPD tool: evidence not perception. <i>European Respiratory Journal</i> , 2017, 50, 1700756.	3.1	0
61	Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , 2017, 37, 440-452.	1.2	21
62	Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations. <i>Pharmacoeconomics</i> , 2017, 35, 43-63.	1.7	36
63	ABC Index: quantifying experienced burden of COPD in a discrete choice experiment and predicting costs. <i>BMJ Open</i> , 2017, 7, e017831.	0.8	11
64	Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes. <i>PLoS ONE</i> , 2017, 12, e0171292.	1.1	0
65	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 179.	1.2	15
66	Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. <i>International Journal of COPD</i> , 2017, Volume 12, 3183-3194.	0.9	30
67	Evaluating Complex Interventions. , 2017, , 297-313.		3
68	Common challenges faced in EU-funded projects on integrated care for vulnerable persons. <i>International Journal of Integrated Care</i> , 2017, 17, 17.	0.1	18
69	Economic Evaluation of Integrated Care. , 2017, , 315-332.		0
70	Modeling the cost-effectiveness of stratified medicine in COPD. , 2017, , .		0
71	Cost-Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 927-935.	1.5	10
72	A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 135.	1.6	13

#	ARTICLE	IF	CITATIONS
73	Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care. <i>BMJ Open</i> , 2016, 6, e011519.	0.8	35
74	THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 46-53.	0.2	32
75	Conceptual model for early health technology assessment of current and novel heart valve interventions. <i>Open Heart</i> , 2016, 3, e000500.	0.9	20
76	Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , 2016, 19, 800-810.	0.1	11
77	Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. <i>Arthritis Care and Research</i> , 2016, 68, 308-317.	1.5	27
78	Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat [®] fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 391-401.	1.0	15
79	“To use or not to use”™: a qualitative study to evaluate experiences of healthcare providers and patients with the assessment of burden of COPD (ABC) tool. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16074.	1.1	8
80	Projecting the COPD population and costs in England and Scotland: 2011 to 2030. <i>Scientific Reports</i> , 2016, 6, 31893.	1.6	48
81	Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 605-616.	0.6	31
82	e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial. <i>European Respiratory Journal</i> , 2016, 48, 758-767.	3.1	54
83	The Assessment of Burden of COPD (ABC) Scale: A Reliable and Valid Questionnaire. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 431-438.	0.7	19
84	Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence. <i>Respiratory Medicine</i> , 2016, 110, 34-45.	1.3	18
85	Cost comparison of two implantable cardiac monitors in two different settings: Reveal XT in a catheterization laboratory vs. Reveal LINQ in a procedure room. <i>Europace</i> , 2016, 18, 919-924.	0.7	22
86	Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. <i>Rheumatology</i> , 2016, 55, 809-816.	0.9	21
87	Impact of financial agreements in European chronic care on health care expenditure growth. <i>Health Policy</i> , 2016, 120, 420-430.	1.4	16
88	Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD Measurements. <i>Calcified Tissue International</i> , 2016, 98, 235-243.	1.5	49
89	Performing Economic Evaluation of Integrated Care: Highway to Hell or Stairway to Heaven?. <i>International Journal of Integrated Care</i> , 2016, 16, 3.	0.1	43
90	External validation of exacerbation and mortality outcomes of health economic decision models for COPD., 2016, , .		0

#	ARTICLE	IF	CITATIONS
91	The assessment of burden of COPD (ABC) tool: What counts most?. , 2016, , .		0
92	Information exchange between primary care (PC) and secondary care (SC): What is considered important in COPD?. , 2016, , .		0
93	COPD medication adherence and quality of life. , 2016, , .		0
94	Exploring the impact of adding a respiratory dimension to the current EQ-5D descriptive system. , 2016, , .		0
95	What should be part of a comprehensive assessment of COPD?. , 2016, , .		0
96	The assessment of burden of COPD tool improves health related quality of life. , 2016, , .		0
97	Prediction models for exacerbations in different COPD patient populations: Results of five large databases. , 2016, , .		0
98	SELFIE, a novel Horizon2020 project on integrated care for multi-morbidity. International Journal of Integrated Care, 2016, 16, 304.	0.1	0
99	Kicking off the Special Interest Group Health Economics in Integrated Care â€œ key questions and actions to move research forward. International Journal of Integrated Care, 2016, 16, 269.	0.1	0
100	Exploring the variation in implementation of a COPD disease management programme and its impact on health outcomes: a post hoc analysis of the RECODE cluster randomised trial. Npj Primary Care Respiratory Medicine, 2015, 25, 15071.	1.1	21
101	A conceptual disease model for adult Pompe disease. Orphanet Journal of Rare Diseases, 2015, 10, 112.	1.2	10
102	Development of an integral assessment approach of health status in patients with obstructive airway diseases: the CORONA study. International Journal of COPD, 2015, 10, 2413.	0.9	18
103	Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. PLoS ONE, 2015, 10, e0138225.	1.1	19
104	Costs and effects of new professional roles: Evidence from a literature review. Health Policy, 2015, 119, 1176-1187.	1.4	65
105	Cost-effectiveness of integrated COPD care: the RECODE cluster randomised trial. BMJ Open, 2015, 5, e007284.	0.8	32
106	Cost-Effectiveness of Disease Management Programs for Cardiovascular Risk and COPD in The Netherlands. Value in Health, 2015, 18, 977-986.	0.1	20
107	Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis. Value in Health, 2015, 18, 100-109.	0.1	4
108	Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 557-559.	0.7	13

#	ARTICLE	IF	CITATIONS
109	Mapping the Clinical Chronic Obstructive Pulmonary Disease Questionnaire onto Generic Preference-Based EQ-5D Values. <i>Value in Health</i> , 2015, 18, 299-307.	0.1	16
110	Comparison of EQ-5D and SF-6D utilities in Pompe disease. <i>Quality of Life Research</i> , 2015, 24, 837-844.	1.5	14
111	Does registration of performance indicators improve health outcomes in COPD?. , 2015, , .		0
112	E-monitoring of asthma therapy to improve compliance in children (E-MATIC). , 2015, , .		1
113	Identifying and explaining the variability in development and implementation costs of disease management programs in the Netherlands. <i>BMC Health Services Research</i> , 2014, 14, 518.	0.9	12
114	Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. <i>BMJ</i> , The, 2014, 349, g5392-g5392.	3.0	118
115	Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. <i>BMC Pulmonary Medicine</i> , 2014, 14, 163.	0.8	51
116	Not Simply More of the Same. <i>Medical Decision Making</i> , 2014, 34, 1048-1058.	1.2	7
117	Informal caregiver strain, preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: Results of a randomised controlled trial. <i>International Journal of Nursing Studies</i> , 2014, 51, 1093-1102.	2.5	18
118	Cochrane corner: is integrated disease management for patients with COPD effective?: TableÂ1. <i>Thorax</i> , 2014, 69, 1053-1055.	2.7	34
119	Exploring the variability of patient costs in disease management programs: a hierarchical modelling approach. <i>Applied Economics</i> , 2014, 46, 940-951.	1.2	5
120	Should I Stay or Should I Go Home? A Latent Class Analysis of a Discrete Choice Experiment on Hospital-At-Home. <i>Value in Health</i> , 2014, 17, 588-596.	0.1	39
121	Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysis. <i>Respiratory Research</i> , 2014, 15, 66.	1.4	63
122	Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool: study protocol of a cluster randomised trial in primary and secondary care. <i>BMC Pulmonary Medicine</i> , 2014, 14, 131.	0.8	13
123	Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants. <i>Cost Effectiveness and Resource Allocation</i> , 2014, 12, 17.	0.6	29
124	Nutritional assessment and therapy in COPD: a European Respiratory Society statement. <i>European Respiratory Journal</i> , 2014, 44, 1504-1520.	3.1	233
125	Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 75.	1.2	26
126	Clinical and economic impact of non-adherence in COPD: A systematic review. <i>Respiratory Medicine</i> , 2014, 108, 103-113.	1.3	176

#	ARTICLE	IF	CITATIONS
127	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. <i>Value in Health</i> , 2014, 17, 525-536.	0.1	41
128	The role of disease management programs in the health behavior of chronically ill patients. <i>Patient Education and Counseling</i> , 2014, 95, 137-142.	1.0	23
129	Development of the Assessment of Burden of COPD tool: an integrated tool to measure the burden of COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14021.	1.1	27
130	Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A cross-sectional study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2014, 23, 30-37.	2.5	28
131	Evidence-based policy making: how cost-effective are disease management programs in the Netherlands?. <i>International Journal of Integrated Care</i> , 2014, 14, .	0.1	0
132	Assessing implementation variations of a disease management program in daily practice: the RECODE case study. <i>International Journal of Integrated Care</i> , 2014, 14, .	0.1	0
133	The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis. <i>BMC Pulmonary Medicine</i> , 2013, 13, 40.	0.8	47
134	RECODE: Design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care. <i>BMC Pulmonary Medicine</i> , 2013, 13, 17.	0.8	30
135	e-Monitoring of Asthma Therapy to Improve Compliance in children using a real-time medication monitoring system (RTMM): the e-MATIC study protocol. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 38.	1.5	32
136	An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, e13-e64.	2.5	2,668
137	Evaluation of health care providers' role transition and satisfaction in hospital-at-home for chronic obstructive pulmonary disease exacerbations: a survey study. <i>BMC Health Services Research</i> , 2013, 13, 363.	0.9	3
138	A Choice That Matters?. <i>Pharmacoeconomics</i> , 2013, 31, 719-730.	1.7	5
139	The Role of Value-of-Information Analysis in a Health Care Research Priority Setting. <i>Medical Decision Making</i> , 2013, 33, 472-489.	1.2	7
140	Exploring payment schemes used to promote integrated chronic care in Europe. <i>Health Policy</i> , 2013, 113, 296-304.	1.4	68
141	Patient preference and satisfaction in hospital-at-home and usual hospital care for COPD exacerbations: Results of a randomised controlled trial. <i>International Journal of Nursing Studies</i> , 2013, 50, 1537-1549.	2.5	36
142	Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 353-360.e2.	1.5	263
143	Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. <i>European Respiratory Journal</i> , 2013, 41, 556-564.	3.1	9
144	Cost-Effectiveness of Early Assisted Discharge for COPD Exacerbations in The Netherlands. <i>Value in Health</i> , 2013, 16, 517-528.	0.1	24

#	ARTICLE	IF	CITATIONS
145	The Road Not Taken: Transferability Issues in Multinational Trials. <i>Pharmacoeconomics</i> , 2013, 31, 863-876.	1.7	7
146	BROADER ECONOMIC EVALUATION OF DISEASE MANAGEMENT PROGRAMS USING MULTI-CRITERIA DECISION ANALYSIS. <i>International Journal of Technology Assessment in Health Care</i> , 2013, 29, 301-308.	0.2	24
147	Integrated disease management interventions for patients with chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2013, , CD009437.	1.5	168
148	The management of cardiovascular disease in the Netherlands: analysis of different programmes. <i>International Journal of Integrated Care</i> , 2013, 13, e028.	0.1	16
149	Early assisted discharge with generic community nursing for chronic obstructive pulmonary disease exacerbations: results of a randomised controlled trial. <i>BMJ Open</i> , 2012, 2, e001684.	0.8	26
150	Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2012, 30, 271-302.	1.7	34
151	Care delivery pathways for Chronic Obstructive Pulmonary Disease in England and the Netherlands: a comparative study. <i>International Journal of Integrated Care</i> , 2012, 12, e40.	0.1	13
152	The potential for integrated care programmes to improve quality of care as assessed by patients with COPD: early results from a real-world implementation study in The Netherlands. <i>International Journal of Integrated Care</i> , 2012, 12, e191.	0.1	15
153	Comparing Methods of Data Synthesis. <i>Pharmacoeconomics</i> , 2011, 29, 239-250.	1.7	8
154	Utility Estimation in Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2011, 29, 917-932.	1.7	26
155	Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2011, 14, 1039-1047.	0.1	30
156	Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. <i>New England Journal of Medicine</i> , 2011, 364, 1093-1103.	13.9	603
157	Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. <i>Health Policy</i> , 2011, 101, 122-132.	1.4	46
158	Is the EQ-5D responsive to recovery from a moderate COPD exacerbation?. <i>Respiratory Medicine</i> , 2011, 105, 1195-1202.	1.3	20
159	Tiotropium Reduces Exacerbations Versus Salmeterol Irrespective Of Baseline ICS Treatment In The Poet-COPD; Study. , 2011, , .		0
160	Seasonal Distribution Of Exacerbations In The Poet-COPD; Study. , 2011, , .		0
161	Adjusting for COPD severity in database research: developing and validating an algorithm. <i>International Journal of COPD</i> , 2011, 6, 669.	0.9	6
162	Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. <i>European Journal of Health Economics</i> , 2011, 12, 397-404.	1.4	11

#	ARTICLE	IF	CITATIONS
163	Evaluation of a large scale implementation of disease management programmes in various Dutch regions: a study protocol. BMC Health Services Research, 2011, 11, 6.	0.9	37
164	Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. European Respiratory Journal, 2011, 37, 508-515.	3.1	152
165	Bottom-up implementation of disease-management programmes: results of a multisite comparison. BMJ Quality and Safety, 2011, 20, 76-86.	1.8	13
166	Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 68-74.	2.5	21
167	Effectiveness and cost-effectiveness of early assisted discharge for Chronic Obstructive Pulmonary Disease exacerbations: the design of a randomised controlled trial. BMC Public Health, 2010, 10, 618.	1.2	25
168	Crossing Borders: Factors Affecting Differences in Cost-Effectiveness of Smoking Cessation Interventions between European Countries. Value in Health, 2010, 13, 230-241.	0.1	26
169	If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. Addiction, 2010, 105, 1088-1097.	1.7	16
170	Association between lung function and exacerbation frequency in patients with COPD. International Journal of COPD, 2010, 5, 435.	0.9	79
171	Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax, 2010, 65, 711-718.	2.7	111
172	Is INTERdisciplinary COMMunity-based COPD management (INTERCOM) cost-effective?. European Respiratory Journal, 2010, 35, 79-87.	3.1	72
173	Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax, 2010, 65, 7-13.	2.7	159
174	Application of a theoretical model to evaluate COPD disease management. BMC Health Services Research, 2010, 10, 81.	0.9	17
175	Efficacy and Costs of Nutritional Rehabilitation in Muscle-Wasted Patients With Chronic Obstructive Pulmonary Disease in a Community-Based Setting: A Prespecified Subgroup Analysis of the INTERCOM Trial. Journal of the American Medical Directors Association, 2010, 11, 179-187.	1.2	113
176	Raising the awareness: projecting the future burden of COPD with the BOLD model. European Respiratory Journal, 2009, 34, 787-789.	3.1	8
177	Self-report versus care provider registration of healthcare utilization: Impact on cost and cost-utility. International Journal of Technology Assessment in Health Care, 2009, 25, 588-595.	0.2	19
178	An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. Advances in Therapy, 2009, 26, 872-885.	1.3	9
179	Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health. Pharmacoeconomics, 2009, 27, 465-477.	1.7	33
180	PMC4 LARGELY IGNORED: THE IMPACT OF THE THRESHOLD VALUE FOR A QALY ON THE IMPORTANCE OF A TRANSFERABILITY FACTOR. Value in Health, 2009, 12, A387.	0.1	0

#	ARTICLE	IF	CITATIONS
181	Treatment with inhaled corticosteroids in asthma is too often discontinued. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 411-422.	0.9	42
182	Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. <i>Value in Health</i> , 2008, 11, 1070-1080.	0.1	52
183	MO3 COMPARING METHODS OF DATA SYNTHESIS: UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL. <i>Value in Health</i> , 2008, 11, A346.	0.1	0
184	PRS42 SMOKING-CESSATION ACROSS BORDERS: TRANSFERABILITY OF COST-EFFECTIVENESS RESULTS. <i>Value in Health</i> , 2008, 11, A459.	0.1	0
185	PMC7 SELF-REPORT VERSUS CAREGIVER REPORT OF HEALTH CARE UTILIZATION: IMPACT ON COST AND COST-EFFECTIVENESS. <i>Value in Health</i> , 2008, 11, A561.	0.1	0
186	Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. <i>Current Medical Research and Opinion</i> , 2008, 24, 51-61.	0.9	67
187	Outcomes for COPD pharmacological trials: from lung function to biomarkers. <i>European Respiratory Journal</i> , 2008, 31, 416-469.	3.1	732
188	Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial. <i>International Journal of COPD</i> , 2008, Volume 3, 443-451.	0.9	29
189	Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. <i>Current Medical Research and Opinion</i> , 2008, 24, 51-61.	0.9	5
190	Cost Consequences of Implementing an Electronic Decision Support System for Ordering Laboratory Tests in Primary Care: Evidence from a Controlled Prospective Study in The Netherlands. <i>Clinical Chemistry</i> , 2007, 53, 213-219.	1.5	40
191	A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2007, 25, 695-711.	1.7	30
192	Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. <i>European Journal of Health Economics</i> , 2007, 8, 123-135.	1.4	77
193	PRS3 COST-EFFECTIVENESS OF ROFLUMILAST IN THE UK:A 1-YEAR STUDY IN PATIENTS WITH SEVERE TO VERY SEVERE COPD. <i>Value in Health</i> , 2006, 9, A260-A261.	0.1	1
194	PRS12 EXPECTED VALUE OF PERFECT INFORMATION: A PRACTICAL EXAMPLE OF REDUCING DECISION UNCERTAINTY BY CONDUCTING ADDITIONAL RESEARCH. <i>Value in Health</i> , 2006, 9, A263-A264.	0.1	0
195	PRS18 MEASURING DISEASE-SPECIFIC UTILITIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE HEALTH- AND EXACERBATION PROFILES. <i>Value in Health</i> , 2006, 9, A265-A266.	0.1	0
196	Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. <i>Respiratory Medicine</i> , 2006, 100, 83-86.	1.3	63
197	Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?. <i>Chest</i> , 2006, 130, 1117-1128.	0.4	177
198	Surgery is more cost-effective than splinting for carpal tunnel syndrome in the Netherlands: results of an economic evaluation alongside a randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2006, 7, 86.	0.8	55

#	ARTICLE	IF	CITATIONS
199	Economic Modeling in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 630-634.	3.5	31
200	Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries. Value in Health, 2005, 8, 32-46.	0.1	95
201	Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions: A Dynamic Modeling Study. Value in Health, 2005, 8, 178-190.	0.1	126
202	A dynamic population model of disease progression in COPD. European Respiratory Journal, 2005, 26, 223-233.	3.1	102
203	Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis) Tj ETQq1 1 0.784314 rgBT /Overlock 107 2005, 365, 1552-1560.	6.3	621
204	MC3 METAMODELLING FORTHE CALCULATION OF THE EXPECTED VALUE OF PERFECT INFORMATION ON INDIVIDUAL MODEL PARAMETERS. Value in Health, 2005, 8, A1-A2.	0.1	0
205	PRS10 PROJECTING THE FUTURE COSTS OF ASTHMA AND COPD IN THE NETHERLANDS. Value in Health, 2005, 8, A214.	0.1	0
206	PRS18 DOES QUALITY OF LIFE OF COPD PATIENTS AS MEASURED BY THE GENERIC EQ-5D DIFFERENTIATE BETWEEN COPD SEVERITY STAGES?. Value in Health, 2005, 8, A216-A217.	0.1	0
207	One-year cost-effectiveness of tiotropiumversusipratropium to treat chronic obstructive pulmonary disease. European Respiratory Journal, 2004, 23, 241-249.	3.1	118
208	Influenza vaccination in asthmatic children: effects on quality of life and symptoms. European Respiratory Journal, 2004, 24, 925-931.	3.1	44
209	Influenza Vaccination in Children with Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 488-493.	2.5	131
210	Cost Effectiveness of Interventions for Lateral Epicondylitis. Pharmacoeconomics, 2004, 22, 185-195.	1.7	52
211	Resource use and risk factors in high-cost exacerbations of COPD. Respiratory Medicine, 2004, 98, 883-891.	1.3	128
212	Does influenza vaccination exacerbate asthma in children?. Vaccine, 2004, 23, 91-96.	1.7	28
213	Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial Setting. Pharmacoeconomics, 2003, 21, 1103-1112.	1.7	54
214	Costs of ankylosing spondylitis in three European countries: the patient's perspective. Annals of the Rheumatic Diseases, 2003, 62, 741-747.	0.5	60
215	Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Annals of the Rheumatic Diseases, 2003, 62, 732-740.	0.5	100
216	Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Annals of the Rheumatic Diseases, 2002, 61, 429-437.	0.5	182

#	ARTICLE	IF	CITATIONS
217	MC3 PROJECTIONS FOR COPD IN THE NETHERLANDS: HOW THE TYPE OF PROJECTION AFFECTS THE ESTIMATED GROWTH IN PREVALENCE. Value in Health, 2002, 5, 455.	0.1	0
218	Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial. Arthritis and Rheumatism, 2002, 47, 459-467.	6.7	130
219	Cost effectiveness of guideline advice for children with asthma: A literature review. Pediatric Pulmonology, 2002, 34, 442-454.	1.0	12
220	Resource Use and Costs of Patients With Glaucoma or Ocular Hypertension: A One-year Study Based on Retrospective Chart Review in the Netherlands. Journal of Glaucoma, 2001, 10, 184-191.	0.8	44
221	The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. European Respiratory Journal, 2001, 17, 329-336.	3.1	47
222	The Impact of Aging and Smoking on the Future Burden of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 590-596.	2.5	190
223	The Cost Effectiveness of Early Treatment with Fluticasone Propionate 250 $\hat{1}$ / ₄ g Twice a Day in Subjects with Obstructive Airway Disease. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 2057-2066.	2.5	45
224	The Economic Effects of Screening for Obstructive Airway Disease: An Economic Analysis of the DIMCA Program. Preventive Medicine, 2000, 30, 302-308.	1.6	11
225	The cost diary. Journal of Clinical Epidemiology, 2000, 53, 688-695.	2.4	293
226	Principles of economic evaluation for interventions of chronic musculoskeletal pain. European Journal of Pain, 1999, 3, 343-353.	1.4	28
227	Chronic low-back pain: What does cognitive coping skills training add to operant behavioral treatment? Results of a randomized clinical trial.. Journal of Consulting and Clinical Psychology, 1999, 67, 931-944.	1.6	114
228	Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. , 1998, 7, 39-51.		80
229	A Short Term Cost-Effectiveness Model For Oral Antidiabetic Medicines in Europe. Pharmacoeconomics, 1998, 13, 317-326.	1.7	10
230	Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma. Pharmacoeconomics, 1998, 14, 671-684.	1.7	33
231	A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe. Pharmacoeconomics, 1998, 14, 709-714.	1.7	0
232	Health economic assessment of behavioural rehabilitation in chronic low back pain: a randomised clinical trial. , 1998, 7, 39.		3
233	Combination of Inhaled Corticosteroids and $\hat{1}$ / ₂ -Agonists in Asthma. BioDrugs, 1996, 6, 489-505.	0.7	5
234	Costs and Effects of Inhaled Corticosteroids and Bronchodilators in Asthma and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 975-982.	2.5	0

#	ARTICLE	IF	CITATIONS
235	Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Economics (United Kingdom), 1994, 3, 333-345.	0.8	101
236	Two-Year Bronchodilator Treatment in Patients with Mild Airflow Obstruction. Chest, 1992, 102, 1384-1391.	0.4	63